Fig. 2: Subgroup analysis of viral suppression in the long-acting and oral therapy groups. | Nature Medicine

Fig. 2: Subgroup analysis of viral suppression in the long-acting and oral therapy groups.

From: Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial

Fig. 2

Proportion of participants with viral suppression below 50 copies per milliliter at week 96, as classified by the FDA snapshot algorithm, shown by randomly assigned treatment group and prespecified subgroups. The point estimate for each subgroup represents the weighted risk difference between the proportion with viral suppression in each treatment group, and the error bars represent the 95% CI for those risk differences. These estimates are obtained using Cochran–Mantel–Haenszel-weighted Miettinen and Nurminen method, without adjustment for third-drug class, including all participants with data available for that subgroup classification. The widths of the CIs have not been adjusted for multiple comparisons and cannot be used to infer treatment effects. The P value is for a two-sided test of homogeneity using the Cochran–Mantel–Haenszel method; a P value of less than 0.05 may indicate evidence of heterogeneity across levels of a stratum, although the threshold has not been adjusted for multiple testing and cannot be used to infer differences in treatment effect between subgroups.

Back to article page